Skip to main content
NCBI home page
Genitourinary Medicine logoLink to Genitourinary Medicine
. 1988 Apr;64(2):118–123. doi: 10.1136/sti.64.2.118

Does lactobacillus vaccine for trichomoniasis, Solco Trichovac, induce antibody reactive with Trichomonas vaginalis?

J F Alderete 1
PMCID: PMC1194170  PMID: 3290091

Abstract

Solco Trichovac is a vaccine of Lactobacillus acidophilus developed for treating trichomoniasis. The efficacy of the vaccine is reportedly due to cross reacting antibody being produced in people immunised with the lactobacillus bacteria. Several techniques, including enzyme linked immunosorbent, indirect immunofluorescence, immunoblot, and radioimmunoprecipitation assays were used to assess the extent of antigenic cross reactivity between Lactobacillus acidophilus and Trichomonas vaginalis. Data show a lack of antigenic relatedness between the Solco Trichovac lactobacilli and several strains of T vaginalis. Furthermore, antiserum to L acidophilus failed to inhibit trichomonad cytadherence or host cell killing, as is suggested by the producers of the Solco Trichovac vaccine.

Full text

PDF
118

Images in this article

120Image
on p.120
121Image
on p.121
122Image
on p.122

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alderete J. F. Antigen analysis of several pathogenic strains of Trichomonas vaginalis. Infect Immun. 1983 Mar;39(3):1041–1047. doi: 10.1128/iai.39.3.1041-1047.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alderete J. F., Demes P., Gombosová A., Valent M., Yánoska A., Fabusová H., Kasmala L., Garza G. E., Metcalfe E. C. Phenotypes and protein-epitope phenotypic variation among fresh isolates of Trichomonas vaginalis. Infect Immun. 1987 May;55(5):1037–1041. doi: 10.1128/iai.55.5.1037-1041.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Alderete J. F. Enzyme linked immunosorbent assay for detecting antibody to Trichomonas vaginalis: use of whole cells and aqueous extract as antigen. Br J Vener Dis. 1984 Jun;60(3):164–170. doi: 10.1136/sti.60.3.164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Alderete J. F., Garza G. E. Specific nature of Trichomonas vaginalis parasitism of host cell surfaces. Infect Immun. 1985 Dec;50(3):701–708. doi: 10.1128/iai.50.3.701-708.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Alderete J. F. Identification of immunogenic and antibody-binding membrane proteins of pathogenic Trichomonas vaginalis. Infect Immun. 1983 Apr;40(1):284–291. doi: 10.1128/iai.40.1.284-291.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Alderete J. F., Kasmala L. Monoclonal antibody to a major glycoprotein immunogen mediates differential complement-independent lysis of Trichomonas vaginalis. Infect Immun. 1986 Sep;53(3):697–699. doi: 10.1128/iai.53.3.697-699.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Alderete J. F., Pearlman E. Pathogenic Trichomonas vaginalis cytotoxicity to cell culture monolayers. Br J Vener Dis. 1984 Apr;60(2):99–105. doi: 10.1136/sti.60.2.99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Alderete J. F., Suprun-Brown L., Kasmala L. Monoclonal antibody to a major surface glycoprotein immunogen differentiates isolates and subpopulations of Trichomonas vaginalis. Infect Immun. 1986 Apr;52(1):70–75. doi: 10.1128/iai.52.1.70-75.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gombosová A., Demes P., Valent M. Immunotherapeutic effect of the lactobacillus vaccine, Solco Trichovac, in trichomoniasis is not mediated by antibodies cross reacting with Trichomonas vaginalis. Genitourin Med. 1986 Apr;62(2):107–110. doi: 10.1136/sti.62.2.107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Martinotti M. G., Martinetto P., Savoia D. Adherence of Trichomonas vaginalis to cell culture monolayers. Eur J Clin Microbiol. 1986 Jun;5(3):320–323. doi: 10.1007/BF02017789. [DOI] [PubMed] [Google Scholar]
  11. Meingassner J. G., Mieth H., Czok R., Lindmark D. G., Müller M. Assay conditions and the demonstration of nitroimidazole resistance in Tritrichomonas foetus. Antimicrob Agents Chemother. 1978 Jan;13(1):1–3. doi: 10.1128/aac.13.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Milovanović R., Grcić R., Stojković L. Serologische Untersuchungen mit Solco Trichovac, einer Vakzine gegen die Trichomonas-vaginalis-Infektion bei der Frau. Gynakol Rundsch. 1982;22 (Suppl 2):39–45. [PubMed] [Google Scholar]
  13. Pavic R., Stojković L. Vaccination with SolcoTrichovac. Immunological aspects of a new approach for therapy and prophylaxis of trichomoniasis in women. Gynakol Rundsch. 1983;23 (Suppl 2):27–38. [PubMed] [Google Scholar]
  14. Steinbüchel A., Müller M. Anaerobic pyruvate metabolism of Tritrichomonas foetus and Trichomonas vaginalis hydrogenosomes. Mol Biochem Parasitol. 1986 Jul;20(1):57–65. doi: 10.1016/0166-6851(86)90142-8. [DOI] [PubMed] [Google Scholar]
  15. Stojković L. New evidence elucidating the mechanism of action of Gynatren/SolcoTrichovac. Gynakol Rundsch. 1984;24 (Suppl 3):29–37. doi: 10.1159/000269923. [DOI] [PubMed] [Google Scholar]

Articles from Genitourinary Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES